The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Curcumin Maintenance Therapy for Ulcerative Colitis: Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Two trials focusing on the maintenance phase of IBD reported disease relapse findings, one of CD (Bommelaer et al., 2020) and one of UC (Hanai et al., 2006).”
From A systematic review of the efficacy and safety of turmeric in the treatment of digestive disorders (2024) · cites this paper as Hanai et al., 2006
In the citing paper
“For UC patients in remission, at 6 months there was a trend toward fewer cases of clinical relapse in the curcumin group compared to placebo; however, low event rates impacted precision of the estimate (Figure 4, top) (Hanai et al., 2006).”
From A systematic review of the efficacy and safety of turmeric in the treatment of digestive disorders (2024) · cites this paper as Hanai et al., 2006
In the citing paper
“In the same patients, at 6 months, the mean CAI and EI scores in the curcumin group slightly decreased from baseline, whereas those of the placebo group increased, resulting in a significant difference of differences in means, favoring the curcumin group (Figure 4, bottom) (Hanai et al., 2006).”
From A systematic review of the efficacy and safety of turmeric in the treatment of digestive disorders (2024) · cites this paper as Hanai et al., 2006
In the citing paper
“At 12 months (i.e., 6 months after the treatment period ended), no significant differences in relapse rates were found (Hanai et al., 2006).”
From A systematic review of the efficacy and safety of turmeric in the treatment of digestive disorders (2024) · cites this paper as Hanai et al., 2006
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sulfasalazine: A potent and specific inhibitor of nuclear factor kappa B
Wahl, C., Liptay, S., Adler, G., & Schmid, R. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci992 · Cited by 742
Research works printed but not linked: 32
- Head, 2003, Inflammatory bowel disease part I: ulcerative colitis-pathophysiology and conventional and alternative treatment options, Altern Med Rev, 8, 247
- Boyko, 1987, Risk of ulcerative colitis among former and current cigarette smokers, N Engl J Med, 316, 707, 10.1056/NEJM198703193161202 · DOI
- Rampton, 1981, Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory drugs, Postgrad Med J, 57, 297, 10.1136/pgmj.57.667.297 · DOI
- Kurina, 2001, Depression and anxiety in people with inflammatory bowel disease, J. Epidemiol Community Health, 55, 716, 10.1136/jech.55.10.716 · DOI · Paper page
- Weber, 2000, Suppression of NF-κB activity by sulfasalazine is mediated by direct inhibition of IκB kinase α and β, Gastroenterology, 119, 1209, 10.1053/gast.2000.19458 · DOI · Paper page
- Bantel, 2000, Mesalazine inhibits activation of transcription factor NF-κB in inflamed mucosa of patients with ulcerative colitis, Am J Gastroenterol, 95, 3452, 10.1111/j.1572-0241.2000.03360.x · DOI
- Xu, 2004, Drug therapy for ulcerative colitis, World J Gastroenterol, 10, 2311, 10.3748/wjg.v10.i16.2311 · DOI
- Hanauer, 2004, Medical therapy of ulcerative colitis, Gastroenterology, 126, 1582, 10.1053/j.gastro.2004.02.071 · DOI
- Hanauer, 2006, Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities, Inflamm Bowel Dis, 12, S3, 10.1097/01.MIB.0000195385.19268.68 · DOI
- Kornbluth, 1995, How effective is current medical therapy for severe ulcerative colitis?, J Clin Gastroenterol, 20, 280, 10.1097/00004836-199506000-00004 · DOI
- Taffet, 1983, Sulphasalazine-adverse effects and desensitization, Dig Dis Sci, 28, 833, 10.1007/BF01296907 · DOI
- Present, 2000, How to do without steroids in inflammatory bowel disease, Inflamm Bowel Dis, 6, 48, 10.1097/00054725-200002000-00009 · DOI
- Devos, 2003, Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy, Dermatology, 206, 388, 10.1159/000069965 · DOI
- Jiang, 1996, Curcumin induces apoptosis in immortalized NIH 3T3 and malignant cancer cell lines, Nutr Cancer, 26, 111, 10.1080/01635589609514468 · DOI
- Singh, 1996, Curcumin inhibits the proliferation and cell cycle progression of human umbilical vein endothelial cell, Cancer Lett, 107, 109, 10.1016/0304-3835(96)04357-1 · DOI
- Huang, 1991, Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells, Proc Natl Avad Sci USA, 88, 5292, 10.1073/pnas.88.12.5292 · DOI · Paper page
- Xu, 1997, Curcumin, a compound with anti-inflammatory and anti-oxidant properties, down-regulates chemokine expression in bone marrow stromal cells, Exp Hematol, 25, 413
- Joe, 1997, Presence of an acidic glycoprotein in the serum of arthritic rats: modulation by capsaicin and curcumin, Mol Cell Biochem, 169, 125, 10.1023/A:1006877928703 · DOI
- Singh, 1995, Activation of transcription factor NF-κB is suppressed by curcumin (diferuloylmethane), J Biol Chem, 270, 2495
- Kumar, 1998, Curcumin (diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of molecules and of nuclear factor-κB activation, Biochem Pharmacol, 55, 775, 10.1016/S0006-2952(97)00557-1 · DOI
- Jobin, 1999, Curcumin blocks cytokine-mediated NF-κB activation and proinflammatory gene expression by inhibiting inhibitory factor I-κB kinase activity, J Immunol, 163, 3474, 10.4049/jimmunol.163.6.3474 · DOI
- Sugimoto, 2002, Curcumin ameliorates trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice, Gastroenterology, 123, 1912, 10.1053/gast.2002.37050 · DOI · Paper page
- Rachmilewitz, 1989, Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial, Br Med J, 298, 82, 10.1136/bmj.298.6666.82 · DOI · Paper page
- Schreiber, 1998, Activation of nuclear factor κB inflammatory bowel disease, Gut, 42, 477, 10.1136/gut.42.4.477 · DOI
- Neurath, 1998, Role of NF-κB in immune and inflammatory responses in the gut, Gut, 43, 856, 10.1136/gut.43.6.856 · DOI · Paper page
- Rogler, 1998, Nuclear factor κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa, Gastroenterology, 115, 357, 10.1016/S0016-5085(98)70202-1 · DOI · Paper page
- Lim, 2004, Controversies with aminosalicylates in inflammatory bowel disease, Rev Gastroenterol Disord, 4, 104
- McIntyre, 1988, Balsalazide in the maintenance treatment of patients with ulcerative colitis: a double-blind comparison with sulphasalazine, Aliment Pharmacol Ther, 2, 237, 10.1111/j.1365-2036.1988.tb00693.x · DOI
- Cheng, 2001, Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high risk or pre-malignant lesions, Anticancer Res, 21, 2895
- Squires, 2003, Relevance of mitogen activated protein kinase (MAPK) and phosphotidylinositol-3-kinase/proteinkinase B (PI3K/PKB) pathways to induction of apoptosis by curcumin in breast cells, Bichem Pharmacol, 65, 361, 10.1016/S0006-2952(02)01517-4 · DOI
- Chan, 1998, In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties, Biochem Pharmacol, 55, 1955, 10.1016/S0006-2952(98)00114-2 · DOI · Paper page
- Chainani-Wu, 2003, Safety and anti-inflammatory activity of curcumin: a component of turmeric (Curcuma longa), J Altern Complement Med, 9, 161, 10.1089/107555303321223035 · DOI · Paper page
Cited by
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
Dignass, A., Lindsay, J. O., Sturm, A., Windsor, A., Colombel, J.-F., Allez, M., D'Haens, G., D'Hoore, A., Mantzaris, G., Novacek, G., et al. (2012) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.002 · Cited by 1,548
Aggarwal, B. B., & Sung, B. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.11.002 · Cited by 1,140
Begum, A. N., Jones, M. R., Lim, G. P., Morihara, T., Kim, P., Heath, D. D., Rock, C. L., Pruitt, M. A., Yang, F., Hudspeth, B., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.137455 · Cited by 604
Soleimani, V., Sahebkar, A., & Hosseinzadeh, H. (2018) · Phytotherapy Research · doi:10.1002/ptr.6054 · Cited by 579
Metadata
- Authors
- Hanai, H., Iida, T., Takeuchi, K., Watanabe, F., Maruyama, Y., Andoh, A., Tsujikawa, T., Fujiyama, Y., Mitsuyama, K., Sata, M., Yamada, M., Iwaoka, Y., Kanke, K., Hiraishi, H., Hirayama, K., Arai, H., Yoshii, S., Uchijima, M., Nagata, T., & Koide, Y.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2006-12
- Volume
- 4
- Issue
- 12
- Pages
- 1502-1506
- ISSN
- 1542-3565
- Cited by
- 569
- References
- 1
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
